Company: PHR
Filing Date: 2025-05-14
Form Type: DEF 14A
Source: 0001412408-25-000027
Chunk: 93

Company: Phreesia, Inc.
Filing Date: 2025-05-14
Form: DEF 14A
Chunk 93
---
 a grantor retained annuity trust of which Mr. Weintraub is the trustee and of which the 2017 Trust is

<div align='center'>69</div>

the beneficiary. Members of Mr. Weintraub's immediate family are the sole beneficiaries of the 2017 Trust.

(13) Consists of 41,762 shares of common stock.

(14) Consists of 5,419 shares of common stock.

(15) Consists of 11,291 shares of common stock.

(16) Consists of (i) 10,216 shares of common stock and (ii) 42,096 shares of common stock underlying stock options exercisable within 60 days of April 24, 2025.

(17) Consists of 17,543 shares of common stock.

(18) Consists of (i) 6,110 shares of common stock and (ii) 58,193 shares of common stock underlying stock options exercisable within 60 days of April 24, 2025.

(19) Consists of (i) 2,579,612 shares of common stock and (ii) 722,385 shares of common stock underlying stock options exercisable within 60 days of April 24, 2025.

<div align='center'>70</div>

### CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, discussed in the sections titled "Executive Compensation" and “Non-Employee Director Compensation” the following is a description of each transaction since the beginning of our last fiscal year and each currently proposed transaction in which:

1. we have been or are to be a participant;

2. the amount involved exceeded or exceeds $120,000; and

3. any of our directors, executive officers, or holders of more than 5% of our capital stock, or any immediate family member of, or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest.

#### Commercial agreements with related parties
Jazz Pharmaceuticals

During the fiscal year ended January 31, 2025, we entered into statements of work with an advertising company for advertisements placed by Jazz Pharmaceuticals plc, or Jazz, pursuant to which we recognized revenue of approximately $1.3 million. Mark Smith, M.D., one of our independent directors, also serves on the board of directors of Jazz. We believe that the terms